CHESTER, Va.--(BUSINESS WIRE)--NEXT Bio-Research Services LLC officially began operations October 1 in 6000 square feet of leased space in the Ironbridge Medical Park, Chester, VA. NEXT Bio continues a 23-year history of providing comprehensive integrated project support to investigators in the biotech and pharmaceutical sectors and in providing medical testing services to physicians using state-of-the-art platforms. NEXT Bio was founded by three long-term friends and colleagues who collectively have more than 100 years’ experience in research and development activities. Start-up funds for the new company were identified through a “friends and family” raise which includes the three founders and two passive investors.
Initially, NEXT Bio will focus on providing pharmacogenomics molecular genetic testing, as well as certain cancer genetic and enzyme therapeutic assays. Each of these test platforms falls under the umbrella of personalized health, and are meant to help physicians guide their treatments based on an individual’s genetic make-up. Pharmacogenomics is predictive of our ability to correctly metabolize drugs used to treat cardiology conditions; our liver health tests currently support the detection of HCV and will soon support diagnosis of other liver diseases, such as Hepatocellular carcinoma. Our asparaginase assay is used by clinicians to monitor effective activity levels during the course of treatment of pediatric (and adult) acute lymphoblastic leukemia, and we will introduce testing for HPV in the coming months. NEXT Bio operates under Good Clinical Laboratory Practices and Good Laboratory Practices and is certified under the Clinical Laboratory Improvement Amendments (CLIA).
“We are excited by the launch of our new Company, and by the opportunity to provide sophisticated technologies for our customers,” said Tom Reynolds, President, NEXT Bio. “Our mission is to deliver essential research and clinical support services and solutions in innovative and cost effective ways, and in so doing, protect and further the health, safety, and privacy of our customer patients.”
Robert B. Harris, Ph.D., CFO and CSO, NEXT Bio, added that “I am delighted to join forces with Tom and Greg and our excellent scientific staff in getting our new venture up and running. We have an established and successful business model and anticipate being profitable in our first year of operations.”
Greg Meyers, COO, who directs the clinical genetics programs at NEXT Bio, commented that “Bringing innovative and new technologies to our client base is an exciting focus of NEXT. We look forward to providing service platforms that use the newest and most robust technologies, while building on tried and true methods already in use.”
NEXT Bio-Research Services LLC is a comprehensive contract research organization offering drug discovery, drug development, and clinical testing services to customers in the biotech and pharma industries, and to doctors, hospitals, clinic, and private patients. Please visit us at www.nextbiollc.com.
